Literature DB >> 12445583

Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction.

Shin-ichi Satoh1, Tamami Yamaguchi, Asako Hitomi, Norihiro Sato, Kazumi Shiraiwa, Ichiro Ikegaki, Toshio Asano, Hiroaki Shimokawa.   

Abstract

This study was designed to investigate possible effects of the Rho-kinase inhibitor, fasudil, on the progression of renal failure in rats with unilateral ureteral obstruction. The renal failure markers monitored were the extent of renal interstitial fibrosis and that of macrophage infiltration. In kidneys with unilateral ureteral obstruction, interstitial fibrosis was observed, using Sirius-Red staining, on day 16 after unilateral ureteral obstruction. Macrophage infiltration was observed by immunohistochemistry, using the antibody, ED1. Interstitial fibrosis and macrophage infiltration were significantly attenuated in fasudil-treated animals. The migration of monocytes in vitro elicited by N-formyl-methionyl-leucyl-phenylalanine was potently inhibited by fasudil and its active metabolite, hydroxyfasudil. These results suggest that inhibition of Rho-kinase produces a reduction of macrophage infiltration and represents a new therapeutic strategy for renal fibrosis, a major factor in the progression to end-stage renal failure. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12445583     DOI: 10.1016/s0014-2999(02)02619-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  21 in total

Review 1.  The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.

Authors:  Rachel S Knipe; Andrew M Tager; James K Liao
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 2.  Myofibroblast repair mechanisms post-inflammatory response: a fibrotic perspective.

Authors:  Casimiro Gerarduzzi; John A Di Battista
Journal:  Inflamm Res       Date:  2016-12-31       Impact factor: 4.575

Review 3.  Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity.

Authors:  C Hahmann; T Schroeter
Journal:  Cell Mol Life Sci       Date:  2009-11-12       Impact factor: 9.261

Review 4.  Rho kinase inhibition in diabetic kidney disease.

Authors:  Radko Komers
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

5.  Crucial role of Rho-nuclear factor-kappaB axis in angiotensin II-induced renal injury.

Authors:  Yuri Ozawa; Hiroyuki Kobori
Journal:  Am J Physiol Renal Physiol       Date:  2007-04-04

Review 6.  Fibrogenesis in kidney transplantation: potential targets for prevention and therapy.

Authors:  Arjang Djamali; Millie Samaniego
Journal:  Transplantation       Date:  2009-11-27       Impact factor: 4.939

7.  Beneficial effects of the Rho kinase inhibitor Y27632 in murine puromycin aminonucleoside nephrosis.

Authors:  Liming Wang; Mathew J Ellis; Timothy A Fields; David N Howell; Robert F Spurney
Journal:  Kidney Blood Press Res       Date:  2008-03-27       Impact factor: 2.687

Review 8.  Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions.

Authors:  Linda Julian; Michael F Olson
Journal:  Small GTPases       Date:  2014-07-10

Review 9.  Rho Kinases and Cardiac Remodeling.

Authors:  Toru Shimizu; James K Liao
Journal:  Circ J       Date:  2016-06-01       Impact factor: 2.993

10.  miR-29c is downregulated in renal interstitial fibrosis in humans and rats and restored by HIF-α activation.

Authors:  Yi Fang; Xiaofang Yu; Yong Liu; Alison J Kriegel; Yanyan Heng; Xialian Xu; Mingyu Liang; Xiaoqiang Ding
Journal:  Am J Physiol Renal Physiol       Date:  2013-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.